We are analyzing https://link.springer.com/article/10.1007/s12016-021-08898-7.

Title:
The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies | Clinical Reviews in Allergy & Immunology
Description:
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ damage, especially the kidney, skin, and central nervous system. Anti-dsDNA antibodies play a pivotal role in SLE, and researchers have developed therapeutic strategies targeting these antibodies. Approaches to reduce anti-dsDNA antibodies via B cell targeted biologics against B cell surface antigens, B cell survival factors, or Bruton’s tyrosine kinase have effectively eliminated B cells. However, their non-specific depletion hampers normal immune system functioning and limits the therapeutic benefits. Thus, scientists have attempted anti-dsDNA antibodies or lupus-specific strategies, such as the immature dendritic cell vaccine and immunoadsorption. Recently, synthetic mimic peptides (hCDR1, pCONs, DWEYS, FISLE-412, and ALW) that directly block anti-dsDNA autoantibodies have attracted attention, which could ameliorate lupus, decrease the serological autoantibody titer, reduce the deposition of renal autoantibodies, and improve pathological performance. These potent small peptide molecules are well tolerated, non-toxic, and non-immunogenic, which have demonstrated a benign safety profile and are expected to be hopeful candidates for SLE management. In this review, we clarify the role of anti-dsDNA antibodies in SLE, mainly focus on the current strategies targeting anti-dsDNA antibodies, and discuss their potential clinical value.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

lupus, article, google, scholar, sle, cas, antidsdna, cell, cells, antibodies, patients, erythematosus, systemic, nephritis, baff, autoantibodies, igg, treatment, study, peptide, rituximab, immunol, arthritis, disease, phase, antigens, immune, renal, antibody, effect, antidna, mice, clinical, human, efficacy, including, based, active, trial, safety, activity, therapy, apoptosis, protein, randomized, rheum, therapeutic, hcdr, iii, receptor,

Topics {✒️}

enable anti-dsdna/anti-nmdar antibodies n-methyl-d-aspartate receptor antibody-dependent cell-mediated cytotoxicity c-jun nh2-terminal kinase anti-dna antibody-targeting organs anti-apoptotic molecule bcl-xl antiphospholipid syndrome anti-dsdna/anti-nmdar antibodies specific antigen-including dsdna anti-dsdna antibody subclass present mhc-antigen complex neutralize anti-dsdna antibodies dna-collodion-charcoal membranes anti-dsdna igg capable augments anti-dsdna igg reduce anti-dsdna antibodies anti-dsdna antibodies immunosuppressive target anti-dsdna antibodies serum anti-dsdna antibodies targeting anti-dsdna antibodies murine anti-dna antibodies p21ras/map kinase pathway anti-dsdna antibodies play article download pdf decreasing anti-dsdna antibodies anti-suprabasin autoantibodies account decreasing autophagosome-lysosome fusion b-cell activating factor humanized anti-cd19 mab recognize bcr-mediated internalized mitogen-activated protein kinase anti-dsdna antibodies contribute attempted anti-dsdna antibodies expand cd4+cd25+ tregs murine anti-dna autoantibodies anti-dna igg contributes enhance endoplasmic-reticulum stress similar mimic-neutralizing activities therapeutic small-molecule mimics anti-dsdna antibodies bind short half-life compromises anti-dsdna antibody long-term disease control huixia wang conceived systemic lupus erythematosus tweak/fn14 signaling pathway antibody-mediated glomerulonephritis tyrosine-protein kinase expressed central nervous system tweak/fn14 activation participates

Questions {❓}

Govoni M, Hanly JG (2020) The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?
Jackson SW, Davidson A (2019) BAFF inhibition in SLE-Is tolerance restored?
Stohl W (2012) Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies
         description:Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ damage, especially the kidney, skin, and central nervous system. Anti-dsDNA antibodies play a pivotal role in SLE, and researchers have developed therapeutic strategies targeting these antibodies. Approaches to reduce anti-dsDNA antibodies via B cell targeted biologics against B cell surface antigens, B cell survival factors, or Bruton’s tyrosine kinase have effectively eliminated B cells. However, their non-specific depletion hampers normal immune system functioning and limits the therapeutic benefits. Thus, scientists have attempted anti-dsDNA antibodies or lupus-specific strategies, such as the immature dendritic cell vaccine and immunoadsorption. Recently, synthetic mimic peptides (hCDR1, pCONs, DWEYS, FISLE-412, and ALW) that directly block anti-dsDNA autoantibodies have attracted attention, which could ameliorate lupus, decrease the serological autoantibody titer, reduce the deposition of renal autoantibodies, and improve pathological performance. These potent small peptide molecules are well tolerated, non-toxic, and non-immunogenic, which have demonstrated a benign safety profile and are expected to be hopeful candidates for SLE management. In this review, we clarify the role of anti-dsDNA antibodies in SLE, mainly focus on the current strategies targeting anti-dsDNA antibodies, and discuss their potential clinical value.
         datePublished:2021-09-20T00:00:00Z
         dateModified:2021-09-20T00:00:00Z
         pageStart:152
         pageEnd:165
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s12016-021-08898-7
         keywords:
            Anti-dsDNA antibody
            Systemic lupus erythematosus (SLE)
            Target therapy
            Therapeutic peptide
            B cell
            Allergology
            Immunology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12016-021-08898-7/MediaObjects/12016_2021_8898_Fig1_HTML.png
         isPartOf:
            name:Clinical Reviews in Allergy & Immunology
            issn:
               1559-0267
            volumeNumber:63
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yaqi Wang
               affiliation:
                     name:The Second Affiliated Hospital of Xi’an Jiaotong University
                     address:
                        name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shengxiang Xiao
               affiliation:
                     name:The Second Affiliated Hospital of Xi’an Jiaotong University
                     address:
                        name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yumin Xia
               affiliation:
                     name:The Second Affiliated Hospital of Xi’an Jiaotong University
                     address:
                        name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Huixia Wang
               url:http://orcid.org/0000-0003-4237-8506
               affiliation:
                     name:The Second Affiliated Hospital of Xi’an Jiaotong University
                     address:
                        name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies
      description:Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ damage, especially the kidney, skin, and central nervous system. Anti-dsDNA antibodies play a pivotal role in SLE, and researchers have developed therapeutic strategies targeting these antibodies. Approaches to reduce anti-dsDNA antibodies via B cell targeted biologics against B cell surface antigens, B cell survival factors, or Bruton’s tyrosine kinase have effectively eliminated B cells. However, their non-specific depletion hampers normal immune system functioning and limits the therapeutic benefits. Thus, scientists have attempted anti-dsDNA antibodies or lupus-specific strategies, such as the immature dendritic cell vaccine and immunoadsorption. Recently, synthetic mimic peptides (hCDR1, pCONs, DWEYS, FISLE-412, and ALW) that directly block anti-dsDNA autoantibodies have attracted attention, which could ameliorate lupus, decrease the serological autoantibody titer, reduce the deposition of renal autoantibodies, and improve pathological performance. These potent small peptide molecules are well tolerated, non-toxic, and non-immunogenic, which have demonstrated a benign safety profile and are expected to be hopeful candidates for SLE management. In this review, we clarify the role of anti-dsDNA antibodies in SLE, mainly focus on the current strategies targeting anti-dsDNA antibodies, and discuss their potential clinical value.
      datePublished:2021-09-20T00:00:00Z
      dateModified:2021-09-20T00:00:00Z
      pageStart:152
      pageEnd:165
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s12016-021-08898-7
      keywords:
         Anti-dsDNA antibody
         Systemic lupus erythematosus (SLE)
         Target therapy
         Therapeutic peptide
         B cell
         Allergology
         Immunology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12016-021-08898-7/MediaObjects/12016_2021_8898_Fig1_HTML.png
      isPartOf:
         name:Clinical Reviews in Allergy & Immunology
         issn:
            1559-0267
         volumeNumber:63
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yaqi Wang
            affiliation:
                  name:The Second Affiliated Hospital of Xi’an Jiaotong University
                  address:
                     name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shengxiang Xiao
            affiliation:
                  name:The Second Affiliated Hospital of Xi’an Jiaotong University
                  address:
                     name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yumin Xia
            affiliation:
                  name:The Second Affiliated Hospital of Xi’an Jiaotong University
                  address:
                     name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Huixia Wang
            url:http://orcid.org/0000-0003-4237-8506
            affiliation:
                  name:The Second Affiliated Hospital of Xi’an Jiaotong University
                  address:
                     name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Clinical Reviews in Allergy & Immunology
      issn:
         1559-0267
      volumeNumber:63
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Second Affiliated Hospital of Xi’an Jiaotong University
      address:
         name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
         type:PostalAddress
      name:The Second Affiliated Hospital of Xi’an Jiaotong University
      address:
         name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
         type:PostalAddress
      name:The Second Affiliated Hospital of Xi’an Jiaotong University
      address:
         name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
         type:PostalAddress
      name:The Second Affiliated Hospital of Xi’an Jiaotong University
      address:
         name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yaqi Wang
      affiliation:
            name:The Second Affiliated Hospital of Xi’an Jiaotong University
            address:
               name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
               type:PostalAddress
            type:Organization
      name:Shengxiang Xiao
      affiliation:
            name:The Second Affiliated Hospital of Xi’an Jiaotong University
            address:
               name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
               type:PostalAddress
            type:Organization
      name:Yumin Xia
      affiliation:
            name:The Second Affiliated Hospital of Xi’an Jiaotong University
            address:
               name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Huixia Wang
      url:http://orcid.org/0000-0003-4237-8506
      affiliation:
            name:The Second Affiliated Hospital of Xi’an Jiaotong University
            address:
               name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
      name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
      name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
      name:Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

External Links {🔗}(339)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Bliss.js
Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.49s.

LINK . SPRINGER . COM {}